National Health Act 1953 - Amendment declaration under subsections 85(2) and 85(2AA) - Amendment determination under subsection 85(2A) - drugs and medicinal preparations (No. PB 44 of 2010)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, established the legislative foundation for the Pharmaceutical Benefits Scheme (PBS), which ensures Australians have reliable, timely, and affordable access to a broad range of medicines. To refine the PBS, the Commonwealth Government amends the Act through legislative instruments, such as the one detailed in this explanatory statement. This particular instrument, F2010L01373, amends declarations under subsections 85(2) and 85(2AA) and the determination under subsection 85(2A) of the Act, which specify the drugs and medicinal preparations available as pharmaceutical benefits, as well as the circumstances under which they may be prescribed. The amendments follow recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC) and are designed to align the availability of certain medicines with clinical effectiveness, safety, and cost-effectiveness considerations. This legislative instrument, effective from 1 June 2010, facilitates the ongoing adjustment of the PBS to meet the evolving healthcare needs of Australians.

Scope and Application

The legislative instrument F2010L01373, which is an amendment to the National Health Act 1953, concerns the Pharmaceutical Benefits Scheme (PBS) administered by the Commonwealth of Australia. The amendments are based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC) and modify the declarations and determinations under subsections 85(2), 85(2AA), and 85(2A) of the Act. These changes pertain to the addition and modification of listed drugs and medicinal preparations, as well as the circumstances under which these pharmaceutical benefits may be prescribed. The amendments, outlined in Schedule 1, include the addition of new drugs such as Alendronic acid with colecalciferol and calcium and Perindopril with amlodipine, the deletion of certain amino acid formulas and mineral mixtures, and alterations to the prescribing conditions of various drugs to ensure consistency across combination products for hypertension. The instrument, effective from 1 June 2010, applies nationally and is subject to the recommendations of the PBAC, which involves extensive consultation with stakeholders from various healthcare sectors.

Key Provisions

The primary operative sections of the National Health Act 1953 Amendment Declaration under subsections 85(2) and 85(2AA), and the Amendment Determination under subsection 85(2A), as amended by legislative instrument number PB 44 of 2010, pertain to the declaration of drugs and medicinal preparations that qualify for pharmaceutical benefits under the Pharmaceutical Benefits Scheme (PBS) and the circumstances under which these benefits can be prescribed. Specifically, subsection 85(2) allows the Minister to declare drugs and medicinal preparations that are eligible for pharmaceutical benefits (section 85(2)). Subsection 85(2AA) empowers the Minister to revoke or vary such declarations, with subsection 85(2AB) requiring the Minister to obtain the written advice of the Pharmaceutical Benefits Advisory Committee (PBAC) if such a revocation or variation would result in a drug or medicinal preparation ceasing to be listed (section 85(2AA)). These sections are instrumental in determining which medications are available under the PBS and under what conditions they can be prescribed to patients. The obligations imposed by this Act on the parties or entities it governs primarily involve the Minister and the PBAC. The Minister is responsible for making the declarations and determinations that establish which drugs and medicinal preparations are included in the PBS and the specific circumstances under which these benefits can be prescribed (section 85(2) and 85(2AA)). The PBAC, on the other hand, provides expert recommendations to the Minister regarding which drugs and medicinal preparations should be included in the PBS, taking into account factors such as medical conditions for which the medicines have been approved, their clinical effectiveness, safety, and cost-effectiveness compared to other treatments (section 101(4)). The Minister must obtain PBAC advice before revoking or varying a declaration that would result in a drug or medicinal preparation ceasing to be listed (section 85(2AB)). There are no explicit offences, penalties, or civil/criminal consequences outlined in this legislative instrument for breaches of the Act. However, it is important to note that any actions taken by the Minister that do not comply with the recommendations of the PBAC or that fail to adhere to the procedural requirements outlined in the Act may be subject to judicial review or other legal challenges. This could potentially lead to the Minister being required to take corrective action or being held accountable for any harm caused by non-compliance with the Act. Furthermore, any failure to adhere to the provisions of the Act could potentially lead to a lack of access to certain medications for patients, which could have significant health implications.